Therapy for Human Immunodeficiency Virus Infection — What Have We Learned?

Abstract

In this issue of the Journal three important articles appear, with major implications for the clinical management of infection with the human immunodeficiency virus (HIV).¹³ Hammer et al.¹ and Katzenstein et al.² describe the clinical and virologic results of the AIDS Clinical Trials Group Study 175 (ACTG 175), a large trial involving more than 2400 HIV-infected persons with CD4 cell counts from 200 to 500 cells per cubic millimeter. This trial clearly shows that antiretroviral therapy in such patients delays the progression of disease to AIDS and reduces mortality. Didanosine alone and the combination of zidovudine with didanosine or . . .